A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) with a Next-generation propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

Trial Identifier: D5985C00009
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: October 2024
Primary Completion Date: February 2025
Study Completion Date: February 2025
Condition: Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

No locations posted.